Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

Mastocytosis Clinical Trial

Official title:

Role of Sclerostin in Mastocytosis Bone Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06440148
• Other study ID #: SCLERMAST01
• Status: Recruiting
• Start date: September 1, 2019
• Est. completion date: December 31, 2026

Study information

• Verified date: May 2024
• Source: Medical University of Lublin
• Contact: Aneta Szudy-Szczyrek, MD., PhD.
• Phone: +48815345468
• Email: aneta.szudy-szczyrek[@]umlub.pl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues.

Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.

Description:

Mastocytosis is a heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs, such as the skin, bone marrow or liver. The skeleton is the most frequent localization of systemic mastocytosis (SM). Bone involvement occurs in approximately 70% of SM patients. Pathogenesis of mastocytosis bone disease is poorly understood.

The aim of our research is to explain the potential role of sclerostin, a recently discovered bone tissue protein, in the pathogenesis of bone changes in patients with mastocytosis.

The study group consists of adult patients with mastocytosis divided according to their clinical variants of disease (aggressive systemic mastocytosis - ASM, systemic mastocytosis with an associated hematological neoplasms SM-AHN, smouldering systemic mastocytosis - SSM, indolent systemic mastocytosis - ISM and cutaneous mastocytosis - CM; and group of healthy volunteers.

The concentration of sclerostin, bioactive sclerostin and expression of the SOST gene in human plasma and HMC-1.2 human mast cell culture supernatants is assessed. The Real-Time PCR method is used to evaluate the expression of sclerostin at the mRNA level, while the concentration of the sclerostin protein and its bioactive form is assessed using the enzyme immunoassay ELISA method. The obtained results are correlated with selected demographic, clinical, laboratory and radiological findings. Low-dose CT scan is used to assess bone changes.

These preliminary results could serve that sclerostin may be a new therapeutic target in patients with mastocytosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2026
• Est. primary completion date: May 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Mastocytosis defined according to WHO criteria

• Known KIT mutation status

Exclusion Criteria:

• History of organ transplant

• Inability to give informed consent

• Pregnancy, Breastfeeding

• Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection

Related Conditions & MeSH terms

• Bones
• Mastocytosis

Intervention

Biological:
• SCLEROSTIN
Pathogenesis of mastocytosis bone disease

Locations

Country	Name	City	State
Poland	Department of Hematooncology and Bone Marrow Transplantation	Lublin	Lubelskie

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Lublin

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	plasma sclerostin measurements (in pmol/l) SOST gene expression by Real-Time PCR dimensions of osteolytic lesions on low-dose computed tomography (in mm) dimensions of osteosclerotic lesions on low-dose computed tomography (in mm)	The Primary Outcome Measures concern: the measurements of plasma levels of sclerostin and its bioactive form in patients with mastocytosis and healthy volunteers; the measurements of levels of sclerostin and its bioactive form in HMC-1.2 human mast cells unstimulated and stimutaled with Il-6	1 year
Primary	dimensions of osteolytic lesions (in mm)	The Primary Outcome Measures concern: - the measurements of the dimensions of osteolytic bone lesions on low-dose computed tomography in patients with mastocytosis	1 year
Primary	dimensions of osteosclerotic lesions (in mm)	The Primary Outcome Measures concern: - the measurements of the dimensions of osteosclerotic bone lesions on low-dose computed tomography in patients with mastocytosis	1 year